Findings

What do systematic reviews say?

6 questions · 10 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 10%GRADE not reported 0 · 0%Very low 0 · 0%Low 7 · 70%Moderate 2 · 20%High 0 · 0%

Interferon‐α alone vs interferon‐α plus bevacizumab

1‐year mortality · previously untreated patients with mRCC

Interferon‐α alone showed no clear difference in 1‐year mortality compared with interferon‐α plus bevacizumab (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.17 [1, 1.36]
2 studies · 1381 participants
Low

Interferon‐α alone vs interferon‐α plus bevacizumab

Quality of life · previously untreated patients with mRCC

The review found no eligible studies for this question.

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Interferon‐α alone vs interferon‐α plus bevacizumab

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Interferon‐α alone probably leads to lower adverse events (grade ≥ 3) compared with interferon‐α plus bevacizumab (moderate certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 0.77 [0.71, 0.84]
2 studies · 1350 participants
Moderate

Interferon‐α alone vs standard targeted therapies

1‐year mortality · previously untreated patients with mRCC

Interferon‐α alone probably leads to higher 1‐year mortality compared with standard targeted therapies (sunitinib or temsirolimus) (moderate certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.3 [1.13, 1.51]
2 studies · 1166 participants
Moderate

Interferon‐α alone vs standard targeted therapies

QoL · previously untreated patients with mRCC

5 findings from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 730 participants
Low
Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 730 participants
Low
Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 730 participants
Low

Show 2 more findings

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1002 participants
Low
Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1002 participants
Low

Interferon‐α alone vs standard targeted therapies

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.17 [1.03, 1.32]
1 study · 408 participants
Low